Karyopharm Therapeutics Inc. (KPTI)
Automate Your Wheel Strategy on KPTI
With Tiblio's Option Bot, you can configure your own wheel strategy including KPTI - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol KPTI
- Rev/Share 1.1663
- Book/Share -1.6895
- PB -2.5215
- Debt/Equity -0.4445
- CurrentRatio 1.3305
- ROIC -3.1056
- MktCap 36805974.0
- FreeCF/Share -1.0068
- PFCF -0.3
- PE -8.3033
- Debt/Assets 0.7165
- DivYield 0
- ROE 0.3658
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Karyopharm to Present at the Jefferies Global Healthcare Conference
Published: June 03, 2025 by: PRNewsWire
Sentiment: Neutral
NEWTON, Mass. , June 3, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team is scheduled to present at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025 at 3:10 p.m.
Read More
Here's Why Karyopharm Therapeutics (KPTI) Is a Great 'Buy the Bottom' Stock Now
Published: May 26, 2025 by: Zacks Investment Research
Sentiment: Positive
Karyopharm Therapeutics (KPTI) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Read More
Does Karyopharm Therapeutics (KPTI) Have the Potential to Rally 521.62% as Wall Street Analysts Expect?
Published: May 19, 2025 by: Zacks Investment Research
Sentiment: Positive
The average of price targets set by Wall Street analysts indicates a potential upside of 521.6% in Karyopharm Therapeutics (KPTI). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Read More
Karyopharm to Participate at the 2025 RBC Capital Markets Global Healthcare Conference
Published: May 19, 2025 by: PRNewsWire
Sentiment: Neutral
NEWTON, Mass. , May 19, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate at the 2025 RBC Capital Markets Global Healthcare Conference in a fireside chat on Wednesday, May 21 at 10:00 a.m.
Read More
Karyopharm Announces Poster Presentation on Selinexor in Myelofibrosis at the 2025 European Hematology Association Annual Meeting
Published: May 14, 2025 by: PRNewsWire
Sentiment: Neutral
NEWTON, Mass. , May 14, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced its abstract has been selected for a poster presentation at the 2025 European Hematology Association Annual Meeting (EHA) being held June 12-15 in Milan, Italy.
Read More
These Analysts Revise Their Forecasts On Karyopharm Therapeutics After Q1 Results
Published: May 13, 2025 by: Benzinga
Sentiment: Neutral
Karyopharm Therapeutics Inc. KPTI reported mixed financial results for the first quarter on Monday.
Read More
Karyopharm Announces 1-for-15 Reverse Stock Split
Published: February 24, 2025 by: PRNewsWire
Sentiment: Neutral
NEWTON, Mass. , Feb. 24, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it will implement a 1-for-15 reverse stock split of the issued shares of the Company's common stock ("Reverse Stock Split"), effective at 5:00 p.m.
Read More
Karyopharm Therapeutics (KPTI) Reports Q4 Loss, Tops Revenue Estimates
Published: February 19, 2025 by: Zacks Investment Research
Sentiment: Negative
Karyopharm Therapeutics (KPTI) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.36 per share a year ago.
Read More
Antengene Announces XPOVIO® Approved for Public Health Insurance Coverage in Taiwan Market, Benefiting More Patients with R/R MM in the Region
Published: February 13, 2025 by: PRNewsWire
Sentiment: Neutral
XPOVIO® is the first XPO1 inhibitor approved in Taiwan for the treatment of adult patients with relapsed/refractory multiple myeloma (R/R MM). After the mainland of China, South Korea, Australia and Singapore, Taiwan market is the fifth APAC market in which XPOVIO® has been approved for public health insurance coverage.
Read More
Karyopharm to Report Fourth Quarter and Full Year 2024 Financial Results on February 19, 2025
Published: February 12, 2025 by: PRNewsWire
Sentiment: Neutral
-- Conference Call Scheduled for Wednesday, February 19, 2025, at 8:00 a.m. ET -- NEWTON, Mass.
Read More
About Karyopharm Therapeutics Inc. (KPTI)
- IPO Date 2013-11-06
- Website https://www.karyopharm.com
- Industry Biotechnology
- CEO Mr. Richard A. Paulson M.B.A.
- Employees 279